The AHA filed its comment letter on the Department of Health and Human Services’ proposed remedy for the unlawful payment cuts to certain hospitals that participate in the 340B Drug Pricing Program following the Supreme Court’s unanimous decision in American Hospital Association v. Becerra. 

The AHA strongly supported HHS’ proposal to make a one-time lump-sum repayment to hospitals for the amounts they were underpaid from 2018 to 2022, as well the proposal to pay 340B hospitals what they would have received in beneficiary cost-sharing had the unlawful 340B payment policy not been in effect. It urged HHS to finalize these aspects of the proposal immediately.    

At the same time, the AHA pressed HHS not to finalize its proposal to recoup funds from hospitals as a “budget neutrality adjustment.” The AHA explained that HHS’ legal and public policy justifications for this proposed recoupment were groundless and, in reality, the agency has “both the legal obligation and legal flexibility to not seek a clawback of funds that hospitals received as a result of HHS’ own mistakes and have long since spent on patient care.” 

Specifically, the AHA stated HHS should not pursue any budget neutrality adjustment. If HHS does, AHA said the department should: 

•    drastically reduce the overall amount; 
•    delay any recoupment until 2026 or later; 
•    finalize the current aspect of the proposal that would spread the “adjustment” across 16 years; and 
•    recoup funds in a way that does not lead to a Medicare Advantage Organization windfall at the expense of hospitals and health systems.

Comments on the proposed rule are due Sept. 5. 
 

Related News Articles

Headline
The Department of Health and Human Services April 18 finalized its rule to establish a 340B Administrative Dispute Resolution process as required under the…
Headline
Sen. John Thune, R-S.D., April 16 updated AHA members on progress to extend telehealth waivers, offering hope that a solution will arise in end-of-year…
Headline
AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the…
Headline
AHA March 12 released a new report from Healthsperien on discounts to 340B hospitals through the 340B Drug Pricing Program relative to drug company revenues…
Headline
The U.S. Court of Appeals for the 8th Circuit March 12 upheld Arkansas’ 340B Drug Pricing Nondiscrimination Act against a constitutional challenge brought by…
Headline
AHA Feb. 29 filed a friend-of-the-court brief in support of a Louisiana law that prohibits drug companies from denying Louisiana hospitals the same 340B…